Efektivitas Rifapentine Pada Pasien Dewasa Dengan Latent Tuberculosis infection : Sebuah Kajian Sistematis
DOI:
https://doi.org/10.21776/ub.pji.2023.008.02.9Keywords:
Efektivitas, Rifapentine, TuberkulosisAbstract
Tuberkulosis (TB) adalah penyakit yang dapat menular akibat tingkat kesehatan yang buruk. Terjadinya infeksi TB pada seseorang yang imunitas tubuhnya baik umumnya dapat menghentikan petumbuhan bakteri TB, tapi terkadang ada sebagian bakteri yang tinggal persisten di dalam tubuh atau terjadi dormant dan imunitas tubuh tidak mampu menghentikan pertumbuhan bakteri TB. Sehingga yang terjadi dalam beberapa bulan seseorang bisa menjadi pasien positif TB. Pada tinjauan sistematis ini bertujuan untuk melihat efektivitas rifapentine pada pasien dengan Latent Tubercolosis infection (LTBI) serta penggunaannya dengan rejimen lain. Proses penelusuran pustaka dilakukan dengan database PubMed pada awal Januari 2011 sampai dengan Januari 2021. Dengan menggunakan kata kunci “ Effectiveness Rifapentine†dan Tuberculosis yang modifikasikan menggunakan operator Boolean yaitu “ANDâ€. Keseluruhan penelitan yang ditemukan dalam kajian ini sebanyak 17 penelitian dari berbagai negara, dan belum ditemukan penelitian yang dilakukan di Indonesia. Dari hasil kajian ini penggunaan terapi dengan kombinasi rifapentine (P) dan isoniazid (H) yang diberikan selama tiga bulan dengan dosis sekali seminggu (disebut 3HP) efektivitasnya sangat baik pada pasien LTBI dan dapat meningkatkan kepatuhan penderita karena pemberian rejimen yang lebih pendek dan menurunkan resiko hepatotosisitas pada penderita dengan riwayat penyakit hati kronis atau peningkatan SGOT.
References
World Health Organization. Global Tuberculosis Report. 2020.
Strategy THEG, For T, Prevention T. Global strategy and targets for tuberculosis prevention , care and control after 2015. 2015;1(March 2014):2015–6.
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Prim. 2016;2(April 2018).
By A, Aap T. American Thoracic Society Targeted Tuberculin Testing and Treatment of Latent. Crit Care Med. 1999;2000 Apr;1(3):S221-47.
Bartlett JG. Priorities for the treatment of latent tuberculosis infection in the united States. Infect Dis Clin Pract. 2004;12(6):381–2.
Schaberg T, Lode H. Treatment of tuberculosis. Dtsch Medizinische Wochenschrift. 1990;115(47):1799–802.
Purohit SD, Sisodia RS, Gupta PR, Sarkar SK ST. Fiberoptic bronchoscopy in the diagnosis of sputum smear negative pulmonary TB. Lung india 1983 [Internet]. 1983;I:143–6. Available from: https://www.cdc.gov/tb/education/corecurr/pdf/chapter4.pdf
C HRISTOPHER C. W HALEN , M.D., J OHN L. J OHNSON , M.D., A LPHONSE O KWERA , M.B., C H .B., D AVID L. H OM , M.S., R OBIN H UEBNER , P H .D., M.P.H., P ETER M UGYENYI , M.B., C H .B., R OY D. M UGERWA , M.B., C H .B., AND J ERROLD J. E LLNER , M.D. FTUG –C AWEREUNRECO, A. TRIAL OF THREE REGIMENS TO PREVENT TUBERCULOSIS IN UGANDAN ADULTS INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS. 1997;337:801–8.
Timothy R. Sterling, M.D., M. Elsa Villarino, M.D., M.P.H., Andrey S. Borisov, M.D., M.P.H., Nong Shang, Ph.D., Fred Gordin, M.D., Erin Bliven-Sizemore, M.P.H., Judith Hackman, R.N., Carol Dukes Hamilton MD, Dick Menzies, M.D., Amy Kerrigan, R.N., M.S.N., Stephen E. Weis, D.O., Marc Weiner, M.D., Diane Wing, R.N., Marcus B. Conde, M.D., Lorna Bozeman, M.S., C. Robert Horsburgh, Jr., M.D., Richard E. Chaisson, M.D. for the TTCPTST. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. N Engl J Med. 2011;365:2155–66.
Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New Regimens to Prevent Tuberculosis in Adults with HIV Infection. N Engl J Med. 2011;365(1):11–20.
Robert Belknap, MD, David Holland, MD, MHS, Pei-Jean Feng, MPH, Joan-Pau Millet, MD, MPH, Joan A. Caylà , MD, PhD, Neil A. Martinson, MBBCh, MPH, Alicia Wright, BS, Michael P. Chen, PhD, Ruth N. Moro, MD, MPH, Nigel A. Scott, MS, Bert Arevalo, BS, CCRP, Jo M for the TTC iAdhere ST. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. HHS Public Access. 2017;176(1):139–48.
Nahata MET and MC, OBJECTIVE: Rifapentine: Its Role in the Treatment of Tuberculosis. Ann Pharmacother. 1999;33(407):1203–10.
Frick M, Bonomo E, Lessem E, Mdluli J, McKenna L, Osih R, et al. An activist’s guide to Rifapentine for the treatment of TB infection. 2019;12.
Kementerian Kesehatan RI. PERATURAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR 67 TAHUN 2016 TENTANG PENANGGULANGAN TUBERKULOSIS. Dinas Kesehat. 2016;163.
Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, et al. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin Infect Dis. 2018;67(2):193–201.
Sun HY, Huang YW, Huang WC, Chang LY, Chan PC, Chuang YC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis [Internet]. 2018;111(May):121–6. Available from: https://doi.org/10.1016/j.tube.2018.05.013
Surey J, Stagg HR, Yates TA, Lipman M, White PJ, Charlett A, et al. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. BMC Infect Dis. 2021;21(1):1–8.
Gao L, Zhang H, Xin H, Liu J, Pan S, Li X, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: A randomised controlled study. Eur Respir J. 2018;52(6).
Bunney, P. E., Zink, A. N., Holm, A. A., Billington, C. J., & Kotz CM. Three Months of Weekly Rifapentine plus Isoniazid for Treatment of M. tuberculosis Infection in HIV Co-infected Persons. Physiol Behav [Internet]. 2017;176(10):139–48. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899978/pdf/nihms775882.pdf
Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017;102(2):321–31.
Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, et al. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015;59(6):3399–405.
Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Barnes GL, et al. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. HHS Public Access. 2019;19(7):780–6.
Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother. 2014;70(4):1106–14.
Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015;61(8):1322–7.
Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and Other Systemic Drug Reactions among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
E. E. Bliven-Sizemore, T. R. Sterling†, N. Shang, D. Benator, K. Schwartzman RR, J. Drobeniuc, N. Bock, M. E. Villarino and the TTC. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Physiol Behav. 2016;63(8):1–18.
Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, et al. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: Nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014;58(6):3035–42.
Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, et al. Xpert MTB/RIF assay shows faster clearance of mycobacterium tuberculosis DNA with higher levels of Rifapentine exposure. J Clin Microbiol. 2016;54(12):3028–33.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Pharmaceutical Journal of Indonesia
This work is licensed under a Creative Commons Attribution 4.0 International License